The estimated Net Worth of Eric E Poma is at least $2.11 Millón dollars as of 27 April 2022. Eric Poma owns over 34,156 units of Molecular Templates Inc stock worth over $380,333 and over the last 7 years he sold MTEM stock worth over $0. In addition, he makes $1,733,740 as Chief Executive Officer, Chief Scientific Officer y Director at Molecular Templates Inc.
Eric has made over 2 trades of the Molecular Templates Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 34,156 units of MTEM stock worth $24,251 on 27 April 2022.
The largest trade he's ever made was exercising 239,896 units of Molecular Templates Inc stock on 26 November 2018 worth over $127,145. On average, Eric trades about 27,405 units every 125 days since 2017. As of 27 April 2022 he still owns at least 277,615 units of Molecular Templates Inc stock.
You can see the complete history of Eric Poma stock trades at the bottom of the page.
Dr. Eric E. Poma Ph.D. serves as Chief Executive Officer, Chief Scientific Officer, Director of the Company. Dr. Poma is the Chief Executive Officer and Chief Scientific Officer of the Company and founded Private Molecular in February 2009, serving on its board of directors since its inception. From March 2005 until September 2008, Dr. Poma was Vice President of Business Development of Innovive Pharmaceuticals (acquired by Cytrx Corporation), a biotechnology company. From 2001 to 2005, he served as the Associate Vice President of Business Development at ImClone Systems, Inc. (now Eli Lilly and Company), a biotechnology company focused on antibody therapeutics. As the founder of Private Molecular and in his role as Chief Scientific Officer, he led the invention of technology underlying the Company’s platform technology and what constitutes the whole of the Company’s current lead and preclinical pipeline candidates. Dr. Poma received his Ph.D. in Microbiology and Immunology and B.A. in Biology from the University of North Carolina at Chapel Hill and his M.B.A. from New York University. Our Board has concluded that Dr. Poma should serve as a director of the Company based on Dr. Poma’s direct involvement in the creation of, and knowledge of, our technology platform and extensive experience in the industry, which provides invaluable insight to our Board on matters involving the Company and its future goals. Our Board has concluded that having the Chief Executive Officer as a director is an optimal way of ensuring the most efficient execution and development of the Company’s business goals and strategies.
As the Chief Executive Officer, Chief Scientific Officer y Director of Molecular Templates Inc, the total compensation of Eric Poma at Molecular Templates Inc is $1,733,740. There are no executives at Molecular Templates Inc getting paid more.
Eric Poma is 48, he's been the Chief Executive Officer, Chief Scientific Officer y Director of Molecular Templates Inc since 2017. There are 12 older and 7 younger executives at Molecular Templates Inc. The oldest executive at Molecular Templates Inc is David Hoffmann, 75, who is the Independent Director.
Eric's mailing address filed with the SEC is C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD., SUITE 100, AUSTIN, TX, 78729.
Over the last 7 years, insiders at Molecular Templates Inc have traded over $22,993,582 worth of Molecular Templates Inc stock and bought 14,744,530 units worth $82,519,716 . The most active insiders traders include Target N Vbb Biotech Ag Bio..., David Hirsch y Capital Partners Iii, Llc L.... On average, Molecular Templates Inc executives and independent directors trade stock every 47 days with the average trade being worth of $532,718. The most recent stock trade was executed by Target N Vbb Biotech Ag Bio... on 2 April 2024, trading 250,000 units of MTEM stock currently worth $587,500.
molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.
Molecular Templates Inc executives and other stock owners filed with the SEC include: